PARP inhibitors are approved for the treatment of breast cancer patients with inherited cancer‐associated BRCA1/2 mutations, and ongoing clinical trials are evaluating the efficacy of PARP inhibitors for the treatment of sporadic, triple‐negative breast cancers that share similarities, or “BRCA‐ness,” with inherited BRCA1/2‐mutant breast cancers.39, 40. This evidence concerns the gene BRCA1 and breast cancer.